Stryker Acquisition Vocera

Transaction summary Key Deal Terms Vocera Financials Integration Highlights Other Considerations Cash tender offer of $79.25 per share ■ Total Equity Value of approximately $2.97B and total Enterprise Value of approximately $3.09B (including convertible notes) ■ Strong business momentum and mid-teen forward revenue growth ■ 2021 expected revenues of $226M-$233M ■ Expected 2021 Adj. EBITDA margin of 15.5% - 17.2%; with Q3 actual of 24.1% stryker ■ Sales synergies represent a significant opportunity as Vocera is underpenetrated compared to our current Acute Care customer base and brings a highly complementary product portfolio OPEX synergies will be driven by reduced G&A and elimination of public company costs ■ Closing expected Q1 2022 Transaction neutral to adjusted EPS for 2022; accretive thereafter ■ Commitment to de-lever and maintain investment grade ratings 11

View entire presentation